ArticleLife (Basel, Switzerland)2022
Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Concurrent thyroid and abdominal diffuse large B-cell lymphoma arising in the milieu of chronic fibrosing thyroiditis.JCEM case reports · 2026Article
- Discriminating inflammation from malignancy with short-dynamic patlak parametric 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Whole-body Dynamic [18F]FDG-PET/CT in Giant Cell Arteritis and Polymyalgia Rheumatica.Clinical nuclear medicine · 2026Article
- Article
- The value of metabolic parameters on dynamicFrontiers in oncology · 2026Article
- Dynamic whole-body positron emission tomography/computed tomography for predicting treatment response to chemoradiotherapy in patients with esophageal cancer.Oncology letters · 2025Article
- Fast 4D-PET parametric imaging computation at the whole field of view level: Reliability under simulated conditions of PET KinetiX, a dedicated software solution.European journal of nuclear medicine and molecular imaging · 2025Article
- Leveraging machine learning with dynamic 18F-FDG PET/CT: integrating metabolic and flow features for lung cancer differential diagnosis.European journal of nuclear medicine and molecular imaging · 2025Article
- Incidental Uptake in Gastrointestinal Tract on 18F-FDG-PET/CT: Is It Worth to Investigate? A Study with 371 Patients.GE Portuguese journal of gastroenterology · 2025Article
- Assessment of image-derived input functions from small vessels for patlak parametric imaging using total-body PET/CT.European journal of nuclear medicine and molecular imaging · 2025Article
- Long-Axial Field-of-View PET Imaging in Patients with Lymphoma: Challenges and Opportunities.PET clinics · 2024Review
- Fluorodeoxyglucose Positron Emission Tomography Evaluation of Chronic Recurrent Multifocal Osteomyelitis.Cureus · 2024Article
- Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.EJNMMI physics · 2024Article
- The role of dynamic, static, and delayed total-body PET imaging in the detection and differential diagnosis of oncological lesions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Case report: When infection lurks behind malignancy: a unique case of primary bone lymphoma mimicking infectious process in the spine.Frontiers in nuclear medicine · 2024Article
- Clinical application of a population-based input function (PBIF) for a shortened dynamic whole-body FDG-PET/CT protocol in patients with metastatic melanoma treated by immunotherapy.EJNMMI physics · 2023Article
- Prognostic value of whole-body dynamicHeliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Background: Investigation of the clinical feasibility of dynamic whole-body (WB) [18F]FDG PET, including standardized uptake value (SUV), rate of irreversible uptake (Ki), and apparent distribution volume (Vd) in physiologic tissues, and comparison between inflammatory/infectious and cancer lesions. Methods: Twenty-four patients were prospectively included to undergo dynamic WB [18F]FDG PET/CT for clinically indicated re-/staging of oncological diseases. Parametric maps of Ki and Vd were generated using Patlak analysis alongside SUV images. Maximum parameter values (SUVmax, Kimax, and Vdmax) were measured in liver parenchyma and in malignant or inflammatory/infectious lesions. Lesion-to-background ratios (LBRs) were calculated by dividing the measurements by their respective mean in the liver tissue. Results: Seventy-seven clinical target lesions were identified, 60 malignant and 17 inflammatory/infectious. Kimax was significantly higher in cancer than in inflammatory/infections lesions (3.0 vs. 2.0, p = 0.002) while LBRs of SUVmax, Kimax, and Vdmax did not differ significantly between the etiologies: LBR (SUVmax) 3.3 vs. 2.9, p = 0.06; LBR (Kimax) 5.0 vs. 4.4, p = 0.05, LBR (Vdmax) 1.1 vs. 1.0, p = 0.18). LBR of inflammatory/infectious and cancer lesions was higher in Kimax than in SUVmax (4.5 vs. 3.2, p < 0.001). LBRs of Kimax and SUVmax showed a strong correlation (Spearman’s rho = 0.83, p < 0.001). Conclusions: Dynamic WB [18F]FDG PET/CT is feasible in a clinical setting. LBRs of Kimax were higher than SUVmax. Kimax was higher in malignant than in inflammatory/infectious lesions but demonstrated a large overlap between the etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.